Hepatitis C: Somber Views of Natural History and Optimistic Views of Interferon Treatment?

References
1. Darby SC, Ewart DW, Giangrande PLF, Spooner RJD, Rizza CR, Dusheiko GM, Lee CA, et al. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. Lancet 1997; 350: 1425-1431[ [ Link previously at www.ncbi.nlm.nih.gov ]].

2. Taylor-Robinson SD, Foster GR, Arora S, Hargreaves S, Thomas HC. Increase in primary liver cancer in the UK, 1979-1994. Lancet 1997; 350: 1142-1143.

3. Deuffic S, Poynard T, Buffat L, Valleron AJ. Trends in primary liver cancer [Letter]. Lancet 1998; 351: 214-215.

4. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997; 349: 825-832[ [ Link previously at www.ncbi.nlm.nih.gov ]].

5. Deuffic S, Buffat L, Poynard T, Valleron AJ. La modelisation de l’histoire naturelle de l’epidemie d’hepatite C permet de predire une augmentation considerable de la mortalite par cancer primitif du foie. Strasbourg. Assosiation Francaise pour Etude du Foie 1997.

6. Nishigushi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, Shiomi S, et al. Randomised trial of effects of interferon-alfa on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346: 1051-1055[ [ Link previously at www.ncbi.nlm.nih.gov ]].

7. Kasahara A, Hayashi N, Mochizuki K, Takayanagi M, Yoshioka K, Kakumu S, Iijima A, et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. HEPATOLOGY 1998; 27: 1394-1402[.

8. Serfaty L, Aumaître H, Chazouillèrres O, Bonnan A-M, Rosmorduc O, Poupon E, Poupon R, et al. Determinants of outcome of compensated HCV-related cirrhosis. HEPATOLOGY 1998; 27: 1435-1440[Abstract].

9. Camma C, Giunta M, Linea C, Pagliaro L. The effect of interferon on the liver in chronic hepatitis C: a quantitative evaluation of histology by meta-analysis. J Hepatol 1997; 26: 1187-1199[ [ Link previously at www.ncbi.nlm.nih.gov ]].

10. Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, Zarski JP. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C. Effects of dose and duration. HEPATOLOGY 1996; 24: 778-789[Abstract].

11. Degos F, Daurat V, Chevret S, Gayno S, Bastie A, Riachi G, Ellouk AS, et al. Reenforced regimin of interferon alfa 2a reduces the incidence of cirrhosis in patients with chronic hepatitis C: a multicenter randomised trial. J Hepatol 1998;in press.

12. Fattovich G, Giustina G, Degos F, Tremolada F, Diaodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112: 463-472[Abstract].

13. Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trepo C, Couzigou P, et al. A randomized trial of three 2b interferon regimens for long term treatment of patients with chronic non-A non-B hepatitis. N Eng J Med 1995; 332: 1457-1462[ [ Link previously at www.ncbi.nlm.nih.gov ]].

14. Davies G, Esteban-Mur R, Rustgi V, Hoefs J, Gordon S, Trepo C, et al. Retreatment of relapse after interferon for chronic hepatitis C: an international randomized controlled trial of interferon plus ribavirin vs interferon alone [Abstract]. HEPATOLOGY 1997; 26: 247A.

Return To Article